On November 10, 2016, the U.S. Food and Drug Administration (FDA) granted a supplemental application approval for Opdivo (nivolumab). This approval specifically pertained to the drug's efficacy, as submitted by its sponsor, Bristol Myers Squibb.
Background
Nivolumab, known commercially as Opdivo, is an established therapeutic agent. Supplemental applications are a common regulatory pathway for already approved drugs to expand their utility. This particular approval, identified as BLA 125554 S-22, signifies an update or expansion of the drug's approved uses based on new clinical evidence demonstrating its efficacy. The "Class: Efficacy" designation confirms that the approval was based on data supporting the drug's effectiveness for a particular condition or patient population.
What this means
The FDA's supplemental efficacy approval for Opdivo (nivolumab) on November 10, 2016, indicates an expansion of the drug's therapeutic scope. While the specific details of the new indication or patient population are not provided in the available data, such approvals typically mean that nivolumab has demonstrated a statistically significant benefit in an additional clinical context. This could involve a new type of cancer, an earlier stage of disease, a different line of treatment, or a specific patient subgroup. For clinicians, this expands the available treatment options and guidelines for utilizing nivolumab. For patients and patient advocates, it suggests broader access to this immunotherapy for potentially new conditions or improved treatment regimens. Researchers may find the underlying data for this approval valuable for further studies into nivolumab's mechanisms and applications.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval record, designated as BLA 125554 S-22, was officially noted on November 10, 2016, and is publicly accessible through the accessdata.fda.gov website.